Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
247 hedge funds and large institutions have $3.5B invested in Clovis Oncology, Inc. in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 93 increasing their positions, 88 reducing their positions, and 41 closing their positions.
135% more call options, than puts
Call options by funds: $191M | Put options by funds: $81.1M
6% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 88
3% less funds holding
Funds holding: 255 → 247 (-8)
15% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 41
16% less capital invested
Capital invested by funds: $4.15B → $3.5B (-$657M)
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$92.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.2M |
| 3 |
PC
PointState Capital
New York
|
+$37.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$85.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$41.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.8M |
| 4 |
O
OrbiMed
New York
|
-$29.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$18.2M |
CLVS Hedge Fund Activity: Q4 2017 in Review
247 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2017, worth a combined $3.5B — down 16% from $4.15B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLVS and 35 opened new positions — a net loss of 6 holders — while 88 trimmed existing stakes and 93 added.
The largest buyer was Carmignac Gestion, opening a new position worth an estimated $92.3M. The largest seller was Citadel Advisors, cutting an estimated $85.9M.
- 247 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2017, down from 255 in Q3 2017.
- Funds reported $3.5B of Clovis Oncology, Inc. stock for Q4 2017, down 16% quarter-over-quarter.
- 35 funds opened new Clovis Oncology, Inc. positions in Q4 2017 and 41 closed out, a net change of -6 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2017 was Carmignac Gestion, an estimated $92.3M added.
- The largest Clovis Oncology, Inc. seller in Q4 2017 was Citadel Advisors, an estimated $85.9M sold.
Based on aggregated 13F filings for Q4 2017.